221 studies found for:    603
Show Display Options
Rank Status Study
1 Completed LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: LFB-R603
2 Completed Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-007)
Condition: Dry Eye Syndromes
Intervention: Drug: cyclosporine
3 Completed Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
Condition: Dry Eye Syndromes
Intervention: Drug: cyclosporine
4 Completed Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-006)
Condition: Dry Eye Syndromes
Intervention: Drug: cyclosporine A
5 Active, not recruiting Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
Condition: Crohn's Disease
Intervention: Drug: adult human mesenchymal stem cells
6 Completed
Has Results
Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
Conditions: Meningitis;   Meningococcal Infection
Intervention: Biological: Polysaccharide Diphtheria Conjugate Vaccine
7 Active, not recruiting Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: adult human mesenchymal stem cells;   Drug: Placebo
8 Completed A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Bortezomilb
9 Completed Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan
Conditions: Acute Lung Injury;   Systemic Inflammatory Response Syndrome
Interventions: Drug: Sivelestat sodium hydrate;   Other: conventional therapy
10 Completed Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Placebo;   Drug: PROCHYMAL adult human mesenchymal stem cells
11 Completed Washington State Community Expedited Partner Treatment (EPT) Trial
Conditions: Gonorrhea;   Neisseria Gonorrhoeae;   Chlamydia Trachomatis
Interventions: Other: Patient delivered partner therapy;   Behavioral: Targeted public health partner services
12 Active, not recruiting Von Hippel-Lindau Disease Genetic Epidemiology Study
Condition: Hippel Lindau Disease
Intervention:
13 Completed Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3
Condition: HIV Infections
Interventions: Drug: Aldesleukin;   Drug: ART
14 Completed
Has Results
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
Condition: Bacterial Conjunctivitis
Interventions: Drug: Besifloxacin;   Drug: Vehicle (Placebo)
15 Terminated Evaluation of Cardiac Compass With OptiVol in the Early Detection of Decompensation Events for Heart Failure
Condition: Congestive Heart Failure
Intervention: Device: Cardiac Compass with OptiVol Fluid Status Monitoring
16 Terminated The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
Condition: HIV Infections
Interventions: Drug: Emivirine;   Drug: Hydroxyurea;   Drug: Delavirdine mesylate;   Drug: Stavudine;   Drug: Didanosine
17 Recruiting Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
Condition: Acute Spinal Cord Injury
Interventions: Drug: SUN13837 injection;   Drug: Placebo
18 Completed A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia
Condition: Neutropenia
Intervention:
19 Terminated
Has Results
A Study of the Efficacy and Safety of MK2578 for the Treatment of Anemia in Patients With Kidney Disease (MK2578-003-AM03-EXT12)
Conditions: Anemia;   Chronic Kidney Disease
Interventions: Drug: MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline;   Drug: MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline;   Drug: MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline
20 Completed
Has Results
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)
Condition: Schizophrenia
Interventions: Drug: MK5757;   Drug: Comparator: Placebo

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years